Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 4, 1997, Pages 291-299

  Conley, Barbara A ^a,b   Egorin, Merrill J ^a,b   Sridhara, Rajeshwari ^a,b   Finley, Rebecca ^a,c   Hemady, Ramzi ^b   Wu, Suhlan ^a,b   Tait, Nancy S ^a,b   Van Echo, David A ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Cancer; Phase I trial; Retinoids

Indexed keywords

RETINOIC ACID; RETINOID;

ACIDOSIS; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN PSEUDOTUMOR; CLINICAL TRIAL; CONJUNCTIVITIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; DRY EYE; DRY SKIN; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; NEOPLASMS; TRETINOIN;

EID: 0031027323     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050575     Document Type: Article

References (22)

1. Adamson PC, Pitot HC, Balis FM, Rubin J, Murphy RF, Poplack DG (1993) Variability in the oral bioavailability of all-trans-retinoic acid. J Natl Cancer Inst 85:993-996
2. Barua AB, Olson JA (1986) Retinoyl beta glucuronide: an endogenous compound of human blood. Am J Clin Nutr 43:481-485
3. Brunzell JD (1988) The hyperlipidemias. In: Wyngaardon JB, Smith LH (eds) Cecil textbook of medicine, Saunders, Philadelphia, pp 1137-1149
4. Bugge CJL, Rodriguez LC, Vane FM (1985) Determination of isotretinoin or etretinate and their major metabolites in human blood by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 3:269-277
5. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709
6. Chen Z-X, Xue YQ, Zhang R, Tao R-F, Xia X-M, Li C, Wang W, Zu WY, Yao X-Z, Ling B-J (1991) A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413-1419
7. Chytil F (1986) Retinoic acid: biochemistry and metabolism. J Am Acad Dermatol 15:741-747.
8. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP (1992) The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292-296
9. Halpern AC, Schuchter LM, Elder DE, Gerry D IV, Elenitsas R, Trock B, Matozzo I (1994) Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 12:1028-1035
10. Hill DL, Struck RF (1983) Pharmacologic disposition of chemopreventive retinoids. Anticancer Res 3:171-180
11. Huang M, Ye Y, Chen S, Chai J, Lu J-X, Zhoa L, Gu L, Wang Z (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572
12. Lee JS, Newman RA, Lippman SM, Huber MH, Monor T, Raber MN, Krakoff IH, Hong WK (1993) Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11:959-966
13. Lotan R (1980) Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605:33-91
14. Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS (1994) Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans retinoic acid: a randomized trial. J Natl Cancer Inst 86:539-543
15. Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr (1992) Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303
16. Muindi JRF, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell RF Jr (1992) Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52:2138-2142
17. Rigas JR, Francis PA, Muindi JRF, Kris MG, Huselton C, DeGrazia F, Orazem JP, Young CW, Warrell RP Jr (1993) Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 85:1921-1926
18. Roberts AB, Lamb LC, Sporn MB (1980) Metabolism of all-trans retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy-to 4-keto-retinoic acid. Arch Biochem Biophys 199:374-383
19. Smith MA, Parkinson DR, Cheson BD, Friedman MA (1992) Retinoids in cancer therapy. J Clin Oncol 10:839-864
20. Vane FM, Bugge CJL, Rodriguez LC, Rosenberger M, Doran TI (1990) Human biliary metabolites of isotretinoin: identification, quantification, synthesis and biological activity. Xenobiotica 20:193-207
21. Warrell R, Frankel S, Miller W et al (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 324:1385-1393
22. Zile MH, Inhorn RC, DeLuca HF (1982) Metabolism in vivo of all-trans-retinoic acid. J Biol Chem 257:3544-3550